BioPharma

The current debate about the US applying tariffs to pharmaceutical imports and demands for PBS reforms is the most ludicrous in the recent history of the program.

The Department of Health, Disability and Ageing has revealed that health spending is under increasing pressure in its Incoming Government Brief to Health Minister Mark Butler.

AusBiotech has marked the first half of 2025 by confirming 27 new member organisations, including multinational biopharmaceutical companies.

Patients Australia has convened a new consortium comprised of a range of private healthcare providers to develop new standards for the telehealth sector.

MedAdvisor CEO and managing director, Rick Ratliff, said, "We are now sharpening our focus on the US business. While near-term market headwinds persist, we remain confident in the strength of our platform, the depth of our client relationships, and the strategic investments positioning us for long-term growth."

The South Australian Government has responded to a significant seasonal flu outbreak by announcing it will fund pharmacies to administer the vaccines to children aged six months to five years.

Setting aside the lack of utility of these documents, which provide virtually incomprehensible explanations for demanding price reductions, the information they contain belongs to the sponsor companies, who have every right to delay or prevent their publication.

Neurotech International (ASX: NTI) has announced the publication of its Phase 1/2 clinical trial results for Rett syndrome in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health.

PYC Therapeutics (ASX:PYC) has announced it is progressing the two-part trial of its PYC-003 for Polycystic Kidney Disease.

The British pharmaceutical industry has cautiously welcomed a new ten-year plan for the country's National Health Service, which shares some characteristics with Australia's HTA Review.

New Zealand's Deputy Prime Minister and Associate Health Minister, David Seymour, will issue an updated letter of expectations to Pharmac before the end of July.

The critical and key point is that the anniversary statutory price reductions legislated as a result of agreements are time-limited, meaning they expire, making a new negotiation almost inevitable and giving the industry leverage.